Table 1.
Summary of ongoing clinical trials with immune checkpoint inhibitors combined with other therapies in RCC or UC.
| Identifier | Phase | Cohort | Combinations | Primary endpoints | Estimated enrollment |
|---|---|---|---|---|---|
| NCT02210117 | Pilot | RCC | Nivolumab vs. nivolumab + bevacizumab vs. nivolumab + ipilimumab | Safety and tolerability | 60 |
| NCT02133742 | Ⅰ | RCC | Pembrolizumab + axitinib | DLT | 60 |
| NCT02348008 | Ⅰ,Ⅱ | RCC | Pembrolizumab + bevacizumab | DLT | 61 |
| NCT02599779 | Ⅱ | RCC | Pembrolizumab + SBRT | PFS | 35 |
| NCT02724878 | Ⅱ | Non-clear cell RCC | Atezolizumab + bevacizumab | ORR | 40 |
| NCT02420821 | Ⅲ | RCC | Atezolizumab + bevacizumab vs. sunitinib | PFS and OS | 830 |
| NCT01441765 | Ⅱ | RCC | CT-011 vs. CT-011 with DC/RCC fusion vaccine | Toxicity and response rate | 44 |
| NCT02437370 | Ⅰ | UC | Pembrolizumab + docetaxel vs. pembrolizumab + gemcitabine | Safety and tolerability | 38 |
| NCT01524991 | Ⅱ | UC | Gemcitabine, cisplatin + ipilimumab | 1-year OS | 36 |
| NCT02619253 | Ⅰ,Ⅱ | RCC and UC | Pembrolizumab + vorinostat | MTD | 42 |
| NCT02496208 | Ⅰ | RCC, UC | Nivolumab + cabozantinib vs. nivolumab + cabozantinib + ipilimumab | DLT | 66 |
DLT, dose limited toxicity; MTD, maximum tolerated dose; ORR, overall response rate; OS, overall survival; PFS, progression free survival; RCC, renal cell carcinoma; UC, urothelial carcinoma.